These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Influenza: recommendations for vaccination and treatment. Mihalopoulos NL; Khan A; Wiese J J La State Med Soc; 2001 Dec; 153(12):596-602. PubMed ID: 11804453 [TBL] [Abstract][Full Text] [Related]
3. [Safety of viral vaccines (a review)]. Peradze TV; Fridman EA Tr Inst Im Pastera; 1979; 52():9-18. PubMed ID: 550552 [No Abstract] [Full Text] [Related]
4. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Tam JS; Capeding MR; Lum LC; Chotpitayasunondh T; Jiang Z; Huang LM; Lee BW; Qian Y; Samakoses R; Lolekha S; Rajamohanan KP; Narayanan SN; Kirubakaran C; Rappaport R; Razmpour A; Gruber WC; Forrest BD; Pediatr Infect Dis J; 2007 Jul; 26(7):619-28. PubMed ID: 17596805 [TBL] [Abstract][Full Text] [Related]
7. Cross-reactive H1N1 antibody responses to a live attenuated influenza vaccine in children: implication for selection of vaccine strains. Lee MS; Yang CF J Infect Dis; 2003 Nov; 188(9):1362-6. PubMed ID: 14593595 [TBL] [Abstract][Full Text] [Related]
13. Valuable data surrounding the priming and boosting abilities of various vaccine technologies. Toback S; Ambrose C Vaccine; 2009 Jan; 27(3):349. PubMed ID: 19027811 [No Abstract] [Full Text] [Related]
14. Pandemic H5N1 influenza vaccine development: an update. El Sahly HM; Keitel WA Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892 [TBL] [Abstract][Full Text] [Related]
15. [Unresolved problems in the specific prevention of influenza]. Fridman EA; Peradze TV Tr Inst Im Pastera; 1982; 59():6-12. PubMed ID: 7187568 [No Abstract] [Full Text] [Related]
16. Development and characterization of a live attenuated influenza B virus vaccine candidate. Seo SU; Byun YH; Lee EY; Jung EJ; Jang YH; Kim HA; Ha SH; Lee KH; Seong BL Vaccine; 2008 Feb; 26(7):874-81. PubMed ID: 18207290 [TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of inactivated vaccines against influenza]. Fridman EA; Peradze TV Tr Inst Im Pastera; 1982; 58():84-94. PubMed ID: 6764983 [No Abstract] [Full Text] [Related]
19. [Which influenza vaccination is the best - with whole virus, split vaccine or subunit vaccines?]. Klenk HD; Stickl H Med Welt; 1981 Jun; 32(25):1008-9. PubMed ID: 7278577 [No Abstract] [Full Text] [Related]
20. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Belshe R; Lee MS; Walker RE; Stoddard J; Mendelman PM Expert Rev Vaccines; 2004 Dec; 3(6):643-54. PubMed ID: 15606348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]